Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Food Effect Study of SMP-100 Formulations in Healthy Volunteers
NCT05029518Phase 1Completed
- Sponsor
- SciMount Pharmatech, Co. Ltd.
- Start
- Sep 2021
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of SMP-100 in Irritable bowel syndrome with diarrhea (IBS-D) (3 arms), sponsored by SciMount Pharmatech, Co. Ltd. Primary endpoints: Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity, Area Under the Plasma Concentration-Time Curve From Time Zero to Last Quantifiable Concentration and 1 more. Started Sep 2021; status: completed.
02
Drugs
SMP-100
03
Conditions
Irritable bowel syndrome with diarrhea (IBS-D)
Beyond the preview
Go deeper on NCT05029518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05029518.